Today’s treatments fail to address the heterogeneity of autoimmune and inflammatory diseases that affect an estimated 7% of the U.S. population. For many of these chronic, progressive diseases, the majority of patients do not respond to current one-size-fits-all treatments, and many experience challenging side effects.
Rheos Medicines is changing the paradigm. We have put into practice a new approach that enables us to develop precision medicines for autoimmune and inflammatory diseases, designed for each subset of patients based on our understanding of what drives these diseases in different patient groups. Using our proprietary MetPM™ platform, the Rheos team elucidates the heterogeneity of underlying autoimmune and inflammatory disease mechanisms through a metabolic lens, addressing the pathways essential to metabolic regulation of multiple immune cell subtypes to drive system-wide transitions in immunologic function. In this way, we will leverage specifically targeted therapies for patients affected by autoimmune and inflammatory diseases, by selecting the right therapy for every patient.
Rheos is taking a major step forward as we focus on treating autoimmune and inflammatory diseases with greater precision.